Pfizer Corporation

Ye Che

Matthew Frank Brown

Justin Ian Montgomery

Philip R Dormitzer

Usa Reilly

Mark Edward Flanagan

Adam Matthew Gilbert

Xiayang Qiu

Anthony Marfat

Mark Edward Ruppen

Matthew Merrill Hayward

Avvari Krishna Prasad

Atli Thorarensen

Rayomand Jal Unwalla

John Isidro Trujillo

Agustin Casimiro-Garcia

Ping Cai

Xin Xu

Jean-Baptiste Telliez

Michael Joseph Melnick

Kena Anne Swanson

Srinivas Kodali

Lorna Del Pilar Nunez

Kristin Rachael Tompkins

KariAnn Sweeney Efferen

Xi Song

Luke David Handke

Alexey Vyacheslavovich Gribenko

Jotham Wadsworth Coe

Michael Joesph Melnick

Jonathan David Langille

Xiaoyuan Sherry Chi

Loren Michael Price

Yuhang Liu

Xiaojie Yao

Jennifer Anne Nicki

Mark Stephen Plummer

Matthew Curtis Griffor

Daniel Paul Uccello

John I Trujillo

Russell Dushin

Richard Andrew Ewin

Thomas Richard Jones

Christopher John O'Donnell

Timothy Allan Johnson

Tamim F Braish

Sidney Xi Liang

Lawrence Nathan Tumey

Seungil Han

Jeffrey Michael Casavant

Laurent Oliver Chorro

Lee Richard Roberts

Jeremy Tyson Starr

Joseph Alan Abramite

Xinzhen Yang

Gary Frederick Filzen

Ludivine Moine

Robert George Konrad Donald

Kyle Paul Heim

Jennifer Young

Natalie Clare Silmon De Monerri

Philip Ralph Dormitzer

Mathew Frank Brown

Kariann Sweeney Efferen

Christopher John O'donnell

Daniel P Uccello

Jeremy Starr

Joseph A Abramite

Polypeptides and cytomegalovirus (CMV) antigens that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). For example, polypeptides stabilized in a conformation alternative to the gB postfusion conformation. Compositions including the polypeptides and uses thereof.

Human cytomegalovirus gB polypeptide

The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

RSV F protein mutants

This disclosure relates to the design ofmutated FimH polypeptides that result in improved biochemical properties and immunogenicity, compositions comprising such polypeptides, and uses thereof.

FimH mutants and uses thereof

The present invention provides a method for treating alopecia using certain pharmaceutically active pyrrolo[2,3-d]pyrimidinyl acrylamides having the structure: or a pharmaceutically acceptable salt thereof, as set forth in the Description.

Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III wherein Q is selected from the group consisting of —P(O)(OH), —P(O)(OH)(OM), —P(O)(OM)and —P(O)(O)M; Mat each occurrence is a pharmaceutically acceptable monovalent cation; and Mis a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

Fluoro-pyridinone phosphates and boronates useful as antibacterial agents

The present invention comprises mutants of a wild-type cytomegalovirus (CMV) glycoprotein B (gB) protein that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB), compositions including the mutants and uses thereof. In some embodiments, the mutant is stabilized in a conformation alternative to the gB postfusion conformation.

Human cytomegalovirus GB polypeptide

The present invention is directed to novel heteroaryl sulfone-based conjugation handles of the formula: (wherein R, R, Het, D, E, X, Y, Z, m, n, p, q, r, s and t are as defined herein), methods for their preparation, their use in synthesizing antibody drug conjugates, and the resulting antibody drug conjugates made with components having heteroaryl sulfone-based conjugation handles.

Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates

The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylam ides and analogues thereof, having the structure: or a pharmaceutically acceptable salt thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides, and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof, having the structure: or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer or diastereomer thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.

N-link hydroxamic acid derivatives useful as antibacterial agents

Growing community of inventors

Groton, CT, United States of America

Ye Che